The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose-dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Pre- O
and O
post-assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

IFNalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
MU O
) O
. O

Randomized B-Claim
trials I-Claim
in I-Claim
fluorouracil I-Claim
( I-Claim
FU I-Claim
) I-Claim
-refractory I-Claim
colorectal I-Claim
cancer I-Claim
demonstrate I-Claim
significant I-Claim
survival I-Claim
advantages I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
irinotecan I-Claim
. I-Claim

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2-4 O
. O

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O

Demographic O
and O
clinical O
factors O
studied O
were O
age O
, O
performance O
status O
, O
dominant O
site O
of O
disease O
and O
preceding O
disease-free O
interval O
( O
DFI O
) O
. O

Patients O
received O
six O
cycles O
of O
either O
gemcitabine-carboplatin O
or O
carboplatin O
. O

The O
phase O
3 O
VISTA O
study O
in O
transplant-ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib-melphalan-prednisone O
( O
VMP O
";" O
nine O
6-wk O
cycles O
) O
vs. O
melphalan-prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

At B-Premise
the I-Premise
10-point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
TDD I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
was I-Premise
11.7 I-Premise
months I-Premise
versus I-Premise
8.4 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.1017 I-Premise
) I-Premise
. I-Premise

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

We O
evaluated O
safety O
and O
efficacy O
of O
IFNalpha O
and O
isotretinoin O
compared O
with O
IFNalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
IIA O
and O
IIB O
. O

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

At O
baseline O
and O
12 O
weeks O
, O
we O
used O
the O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
and O
Fatigue O
Severity O
Scale O
( O
FSS O
) O
as O
primary O
outcomes O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
and O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
for O
secondary O
outcomes O
. O

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
Cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O

The O
mean O
follow-up O
period O
was O
53.6 O
months O
. O

Arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double-blind O
placebo-controlled O
randomised O
phase O
II O
trial O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

Stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Follow-up O
assessments O
were O
at O
2 O
, O
4 O
and O
8 O
weeks O
postdischarge O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
ALT O
is O
a O
safe O
method O
and O
whether O
there O
are O
differences O
in O
adherence O
, O
limb O
volume O
, O
and O
quality O
of O
life O
between O
women O
who O
perform O
only O
self-management O
treatment O
and O
women O
who O
participate O
as O
well O
in O
ALT O
. O

During O
the O
3-day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1-3 O
tablets O
of O
oxycodone/paracetamol O
( O
5/325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

With B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one-year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue/malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
arms I-Premise
in I-Premise
the I-Premise
extent I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
as I-Premise
measured I-Premise
by I-Premise
physician I-Premise
, I-Premise
in I-Premise
oral I-Premise
toxicities I-Premise
as I-Premise
recorded I-Premise
by I-Premise
patients I-Premise
, I-Premise
or I-Premise
in I-Premise
radiotherapy I-Premise
delays I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
44.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
1.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.18 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

Chemotherapy-naïve O
patients O
with O
measurable O
unresectable O
and/or O
metastatic O
gastric O
carcinoma O
, O
a O
performance O
status O
< O
or= O
1 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
randomly O
received O
< O
or= O
eight O
3-weekly O
cycles O
of O
ECF O
( O
epirubicin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
cisplatin O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
and O
fluorouracil O
[ O
FU O
] O
200 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
21 O
) O
, O
TC O
( O
docetaxel O
initially O
85 O
mg/m O
( O
2 O
) O
on O
day O
1 O
[ O
later O
reduced O
to O
75 O
mg/m O
( O
2 O
) O
as O
a O
result O
of O
toxicity O
] O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
or O
TCF O
( O
TC O
plus O
FU O
300 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
14 O
) O
. O

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open-label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Four O
weeks O
later O
, O
all O
patients O
received O
pamidronate O
120 O
mg O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

Pain O
is O
1 O
of O
the O
most O
common O
symptoms O
that O
a O
cancer O
patient O
would O
experience O
. O

A O
total O
of O
769 O
patients O
were O
randomized O
to O
EXE O
25 O
mg/d O
( O
n O
= O
366 O
) O
or O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O

At B-Claim
higher I-Claim
doses I-Claim
, I-Claim
however I-Claim
, I-Claim
TMX I-Claim
inhibits I-Claim
HCC I-Claim
through I-Claim
ER-independent I-Claim
mechanisms I-Claim
. I-Claim

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

To O
investigate O
whether O
the O
effect O
of O
hypofractionated O
thoracic O
radiotherapy O
( O
TRT O
) O
is O
comparable O
to O
more O
standard O
fractionated O
radiotherapy O
( O
RT O
) O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

They O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
μg/kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

Forty O
patients O
( O
31 O
men O
and O
9 O
women O
) O
were O
enrolled O
and O
received O
3-5 O
courses O
of O
treatment O
. O

Fat-free B-Premise
mass I-Premise
showed I-Premise
an I-Premise
intergroup I-Premise
difference I-Premise
in I-Premise
favor I-Premise
of I-Premise
group I-Premise
B I-Premise
after I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
remission I-Premise
rates I-Premise
( I-Premise
P I-Premise
= I-Premise
0.031 I-Premise
) I-Premise
, I-Premise
more I-Premise
depression-free I-Premise
days I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
less I-Premise
functional I-Premise
impairment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.011 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.039 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
than I-Premise
usual I-Premise
care I-Premise
participants I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16.9 I-Premise
and I-Premise
17.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59.62 I-Premise
% I-Premise
and I-Premise
65.87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27.28 I-Premise
% I-Premise
and I-Premise
27.93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Between O
January O
1 O
, O
2007 O
, O
and O
November O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
EOF O
or O
TOF O
. O

However B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
QoL I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
. I-Premise

Transfusion O
use O
was O
low O
during O
the O
study O
in O
both O
groups O
. O

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short-term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

CBT-I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

SCLC O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
with I-Premise
10 I-Premise
% I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
partial I-Premise
response I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
than I-Premise
for I-Premise
those I-Premise
taking I-Premise
AC I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
with I-Premise
7 I-Premise
% I-Premise
CR I-Premise
, I-Premise
39 I-Premise
% I-Premise
PR I-Premise
) I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

Assessments O
included O
weight O
, O
symptoms O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
, O
and O
quality O
of O
life O
by O
the O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
( O
FAACT O
) O
questionnaire O
. O

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health-related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT-B+4 O
) O
. O

Seven O
hundred O
fifty-two O
patients O
( O
374 O
QW O
patients O
";" O
378 O
EDS O
patients O
) O
received O
≥1 O
dose O
of O
darbepoetin O
alfa O
and O
were O
included O
in O
the O
analysis O
. O

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

All O
statistical O
tests O
were O
two-sided O
. O

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

Compared B-Premise
with I-Premise
placebo I-Premise
, I-Premise
erlotinib I-Premise
maintenance I-Premise
therapy I-Premise
prolonged I-Premise
progression-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
by I-Premise
41 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho-educational O
intervention O
) O
or O
to O
a O
waiting-list O
control O
group O
. O

The B-Premise
primary I-Premise
outcome I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
-16.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-28.34 I-Premise
to I-Premise
-5.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

Increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O

Prospective O
, O
randomized O
, O
controlled O
trial O
. O

In O
a O
previous O
phase O
II O
trial O
, O
5-fluorouracil O
( O
5-FU O
) O
plus O
cisplatin O
( O
FUP O
) O
yielded O
a O
26.5 O
% O
response O
rate O
and O
a O
29 O
% O
survival O
rate O
at O
1 O
year O
. O

From O
February O
2007 O
to O
July O
2008 O
, O
116 O
patients O
were O
enrolled O
and O
113 O
were O
included O
in O
the O
intent-to-treat O
population O
: O
57 O
patients O
in O
the O
E O
group O
and O
56 O
patients O
in O
the O
V O
group O
. O

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

Consistent O
with O
the O
2-year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient-reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
tamoxifen I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18.5 I-Premise
% I-Premise
vs. I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34.0 I-Premise
% I-Premise
vs. I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17.3 I-Premise
% I-Premise
vs. I-Premise
8.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

We O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
BEP I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good-prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
BEP I-Claim
regimen I-Claim
. I-Claim

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Group B-Premise
differences I-Premise
were I-Premise
smaller I-Premise
within I-Premise
the I-Premise
psychosocial I-Premise
domain I-Premise
, I-Premise
although B-Premise
trends I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

Patients O
and O
investigators O
were O
masked O
to O
CA125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

Total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs. I-Premise
euro8819 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
. I-Premise

The O
primary O
end-point O
was O
acute O
grade O
≥ O
2 O
toxicity O
. O

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

Toxicity B-Premise
( I-Premise
WHO I-Premise
grade I-Premise
3-4 I-Premise
) I-Premise
was I-Premise
lower I-Premise
with I-Premise
FU I-Premise
than I-Premise
with I-Premise
FUP I-Premise
( I-Premise
20 I-Premise
% I-Premise
versus I-Premise
48 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
versus I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
4 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
toxicity-related I-Premise
deaths I-Premise
( I-Premise
one I-Premise
versus I-Premise
four I-Premise
early I-Premise
in I-Premise
the I-Premise
trial I-Premise
) I-Premise
. I-Premise

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

Myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise

The B-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75.0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55.7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85.6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise

The O
scapula-oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O

Eligible O
patients O
had O
to O
have O
a O
history O
of O
primary O
breast O
cancer O
without O
evidence O
of O
detectable O
disease O
and O
14 O
or O
more O
weekly O
hot O
flashes O
for O
at O
least O
1 O
month O
. O

In O
contrast O
, O
the O
energy O
needs O
of O
malignant O
tumors O
are O
almost O
entirely O
met O
by O
glucose O
. O

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

The B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-P I-Premise
total I-Premise
score I-Premise
( I-Premise
12·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11·1-14·0 I-Premise
] I-Premise
vs I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
7·4-10·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·66-0·92 I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate-cancer-specific I-Premise
subscale I-Premise
( I-Premise
11·1 I-Premise
months I-Premise
[ I-Premise
8·6-13·8 I-Premise
] I-Premise
vs I-Premise
5·8 I-Premise
months I-Premise
[ I-Premise
5·5-8·3 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·60-0·83 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

Gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
RP I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

However B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

Ninety-one O
patients O
were O
randomized O
, O
47 O
to O
fludarabine O
and O
44 O
to O
CVP O
. O

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Between O
Nov O
26 O
, O
2007 O
, O
and O
Dec O
12 O
, O
2011 O
, O
we O
enrolled O
and O
randomly O
allocated O
218 O
patients O
to O
treatment O
: O
80 O
to O
the O
nurse O
group O
, O
70 O
to O
the O
gastroenterologist O
group O
, O
and O
68 O
to O
the O
booklet O
group O
( O
figure O
) O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

However O
, O
because O
of O
toxicity O
associated O
with O
long-term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

Arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

Patients O
were O
randomized O
to O
fludarabine O
( O
25 O
mg/m O
( O
2 O
) O
intravenously O
on O
days O
1 O
to O
5 O
, O
every O
28 O
days O
) O
or O
CVP O
( O
cyclophosphamide O
750 O
mg/m O
( O
2 O
) O
and O
vincristine O
1.2 O
mg/m O
( O
2 O
) O
both O
intravenously O
on O
day O
1 O
and O
prednisone O
40 O
mg/m O
( O
2 O
) O
orally O
on O
days O
1 O
to O
5 O
, O
every O
21 O
days O
) O
. O

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
opioid I-Premise
doses I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
study I-Premise
were I-Premise
found I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The O
management O
of O
cancer-related O
anorexia/cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

Between O
March O
2007 O
and O
April O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

A O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O

Incremental O
cost-utility O
ratios O
( O
ICURs O
) O
were O
calculated O
assuming O
a O
6 O
% O
annual O
discount O
rate O
for O
costs O
and O
a O
1.5 O
% O
annual O
discount O
rate O
for O
benefits O
. O

After O
a O
median O
follow-up O
of O
5.5 O
years O
, O
277 O
events O
have O
been O
reported O
. O

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in-hospital I-Premise
compared I-Premise
with I-Premise
seven I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
0·35 I-Premise
, I-Premise
0·16-0·78 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

Of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6-month O
assessment O
and O
399 O
completed O
the O
12-month O
assessment O
. O

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

Endpoints O
were O
overall O
survival O
, O
progression-free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor-prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

The O
combination O
of O
cisplatin O
with O
Mitomycin O
and O
Vinblastine O
was O
one O
of O
the O
most O
frequently O
used O
in O
the O
palliative O
setting O
at O
the O
time O
of O
design O
of O
our O
study O
. O

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

A O
validated O
mucositis O
scoring O
system O
was O
used O
. O

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Patient O
HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
TSP O
) O
, O
time O
to O
deterioration O
( O
TTD O
) O
in O
Trial O
Outcome O
Index O
( O
TOI O
) O
and O
TTD O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Thirty-six O
patients O
were O
treated O
. O

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

ORR B-Premise
was I-Premise
25.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ECF I-Premise
, I-Premise
18.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
TC I-Premise
, I-Premise
and I-Premise
36.6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

Tumor B-Claim
characteristics I-Claim
and I-Claim
wound I-Claim
complications I-Claim
have I-Claim
a I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
patient I-Claim
function I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
and I-Premise
survival I-Premise
outcomes I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
randomised I-Premise
and I-Premise
non-randomised I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

This O
analysis O
evaluates O
the O
effectiveness O
of O
the O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
ICD-9 O
cancer O
diagnosis O
. O

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

Patients O
were O
randomly O
assigned O
to O
the O
8-week O
MBSR O
program O
or O
standard O
care O
. O

In B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
event-rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
significance I-Premise
level I-Premise
for I-Premise
group I-Premise
differences I-Premise
was I-Premise
P I-Premise
= I-Premise
.0006 I-Premise
for I-Premise
survival I-Premise
to I-Premise
10 I-Premise
years I-Premise
. I-Premise

The B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
FLIC I-Premise
and I-Premise
FACT-L I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
KPS I-Premise
values I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

Intrusions B-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
fatigue I-Premise
, I-Premise
sleep I-Premise
, I-Premise
breast I-Premise
cancer-specific I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
mental I-Premise
functioning I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
remained I-Premise
worse I-Premise
over I-Premise
time I-Premise
. I-Premise

The B-Premise
event-free I-Premise
period I-Premise
( I-Premise
EFP I-Premise
) I-Premise
, I-Premise
radiologic I-Premise
course I-Premise
of I-Premise
disease I-Premise
, I-Premise
and I-Premise
survival I-Premise
did I-Premise
not I-Premise
improve I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O

Imatinib O
is O
the O
standard O
treatment O
of O
advanced O
GI O
stromal O
tumors O
( O
GISTs O
) O
. O

A O
multi-method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

Randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O

Exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

A O
cancer O
center O
in O
an O
academic O
health O
science O
center O
in O
the O
northeastern O
United O
States O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

Our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhTSH I-Claim
preserves I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
RI I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim

Immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
TS I-Premise
. I-Premise

After O
stratification O
according O
to O
performance O
status O
( O
PS O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
Phase O
II O
trials O
with O
5-FU/6S-LV O
and O
EEP-L O
, O
respectively O
. O

Randomization O
totaled O
130 O
patients O
( O
GE O
= O
86 O
, O
G O
= O
44 O
) O
";" O
121 O
patients O
were O
treated O
( O
GE O
= O
82 O
, O
G O
= O
39 O
) O
. O

Nutritional O
intake O
( O
diet O
history O
) O
, O
status O
( O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QoL O
( O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
, O
and O
3 O
months O
after O
radiotherapy O
. O

Pretreatment O
characteristics O
were O
evenly O
distributed O
between O
the O
two O
arms O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

Median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

We O
evaluated O
QOL O
data O
from O
874 O
pre- O
and O
perimenopausal O
women O
with O
lymph O
node-negative O
breast O
cancer O
who O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
classical O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
( O
CMF O
) O
chemotherapy O
, O
ovarian O
suppression O
with O
goserelin O
for O
24 O
months O
, O
or O
six O
courses O
of O
classical O
CMF O
followed O
by O
18 O
months O
of O
goserelin O
. O

Patient O
blinding O
was O
successful O
in O
both O
arms O
. O

Study O
follow-up O
was O
completed O
July O
2012 O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

We O
then O
compared O
the O
FACT-An O
data O
from O
the O
Internet O
survey O
with O
the O
QOL O
data O
of O
a O
375-patient O
randomized O
, O
double-blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O

Breast O
cancer O
patients O
( O
N O
= O
354 O
) O
receiving O
chemotherapy O
were O
randomly O
assigned O
in O
1:1 O
ratio O
to O
epoetin O
alfa O
( O
40,000 O
U O
qw O
) O
or O
standard O
of O
care O
( O
SOC O
) O
. O

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

If O
replicated O
in O
larger O
and O
more O
focused O
trials O
, O
aerobic O
exercise O
may O
be O
an O
attractive O
option O
to O
manage O
sleep O
dysfunction O
in O
patients O
with O
cancer O
because O
of O
its O
favorable O
safety O
profile O
and O
other O
documented O
health O
benefits O
. O

Hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0.064 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.016-0.112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0.054 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.007-0.102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

The O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O

Median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

Patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
";" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2/group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) I-Premise
. I-Premise

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Energy B-Premise
intake I-Premise
after I-Premise
RT I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

Fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
QOL O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O

Global B-Claim
health I-Claim
status/QOL I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ECF I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log-rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

Minimum O
followup O
was O
12 O
months O
. O

Fifty-seven O
( O
57 O
) O
women O
met O
inclusion O
criteria O
and O
53 O
were O
randomized O
to O
the O
study O
. O

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

A B-Premise
path I-Premise
model I-Premise
revealed I-Premise
that I-Premise
intervention I-Premise
participation I-Premise
directly I-Premise
improved I-Premise
health I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
. I-Premise

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

Seventy-six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

All O
male O
participants O
were O
3-month O
to O
5-year O
survivors O
of O
localized O
prostate O
carcinoma O
who O
had O
been O
treated O
with O
radical O
prostatectomy O
or O
radiation O
therapy O
, O
and O
were O
married O
or O
in O
a O
committed O
relationship O
. O

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face-to-face O
[ O
FtF O
] O
and O
over-the-telephone O
[ O
Tel O
] O
) O
an O
8-month O
translational O
exercise O
intervention O
, O
commencing O
6-weeks O
post-breast O
cancer O
surgery O
( O
PS O
) O
. O

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self-report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

Participants O
drank O
4 O
oz O
. O

The O
median O
follow-up O
was O
61 O
months O
. O

The B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
SUI I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim

The B-Premise
ORR I-Premise
was I-Premise
also I-Premise
higher I-Premise
with I-Premise
AT I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
involvement I-Premise
( I-Premise
58 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
";" I-Premise
liver I-Premise
, I-Premise
62 I-Premise
% I-Premise
v I-Premise
42 I-Premise
% I-Premise
";" I-Premise
lung I-Premise
, I-Premise
58 I-Premise
% I-Premise
v I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
three I-Premise
or I-Premise
more I-Premise
organs I-Premise
involved I-Premise
( I-Premise
59 I-Premise
% I-Premise
v I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
or I-Premise
prior I-Premise
adjuvant I-Premise
CT I-Premise
( I-Premise
53 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise

Between-group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated-measures O
analysis O
, O
and O
reported O
P O
values O
are O
two-sided O
. O

Patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise

However B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Taking B-Claim
a I-Claim
pre-treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

In O
the O
SUSTENT O
study O
, O
patients O
were O
randomized O
to O
GJJ O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

Overall B-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0-10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1-month I-Premise
outcomes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
study I-Premise
arms I-Premise
for I-Premise
patients I-Premise
with I-Premise
mutated I-Premise
KRAS I-Premise
tumors I-Premise
. I-Premise

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

Similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first-and I-Premise
second-line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second-line I-Premise
therapy I-Premise
. I-Premise

The O
patients O
were O
randomized O
to O
either O
daunomycin-cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin-cytosine O
arabinoside O
with O
GM-CSF O
( O
GM-CSF O
arm O
: O
n O
= O
157 O
) O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
urinary I-Premise
markers I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
urinary I-Premise
markers I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
decreased I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
either I-Premise
dose I-Premise
( I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

Seventy-two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Because O
we O
previously O
found O
that O
change O
in O
self-efficacy O
for O
PA O
did O
not O
vary O
by O
group O
assignment O
, O
the O
relationship O
between O
change O
in O
self-efficacy O
and O
PA O
at O
2-year O
follow-up O
was O
examined O
across O
study O
conditions O
. O

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24-hour I-Premise
infusion I-Premise
. I-Premise

Urinary B-Premise
function I-Premise
declined I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V285 I-Premise
was I-Premise
0.4 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
bother B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
or I-Premise
the I-Premise
EUS I-Premise
V240 I-Premise
was I-Premise
63 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
";" I-Premise
irritation B-Premise
increased I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
95 I-Premise
% I-Premise
( I-Premise
ρ=-0.37 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
and I-Premise
the I-Premise
EUS I-Premise
V265 I-Premise
was I-Premise
24 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
and O
urgency B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99.5 I-Premise
% I-Premise
( I-Premise
ρ=-0.38 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Women O
enrolled O
in O
the O
study O
intervention O
were O
on O
average O
55 O
years O
old O
, O
predominantly O
Caucasian O
( O
79 O
% O
) O
, O
married O
( O
57 O
% O
) O
, O
and O
a O
median O
of O
4 O
years O
postprimary O
treatment O
. O

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0-900 O
) O
. O

Costs O
of O
opioid O
therapy O
, O
supportive O
drugs O
, O
and O
other O
analgesic O
drugs O
were O
also O
evaluated O
. O

Nutritional O
intake O
( O
determined O
by O
diet O
history O
) O
and O
status O
( O
determined O
by O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QOL O
( O
determined O
by O
the O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
[ O
EORTC O
QLQ-C30 O
] O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
of O
RT O
, O
and O
at O
3 O
months O
. O

Patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

Two O
hundred O
forty-six O
of O
302 O
patients O
randomly O
assigned O
provided O
complete O
data O
at O
6 O
weeks O
. O

A B-Claim
clinical I-Claim
assessment I-Claim
and I-Claim
intervention I-Claim
program I-Claim
for I-Claim
menopausal I-Claim
symptom I-Claim
management I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
, I-Claim
leading I-Claim
to I-Claim
reduction I-Claim
in I-Claim
symptoms I-Claim
and I-Claim
improvement I-Claim
in I-Claim
sexual I-Claim
functioning I-Claim
. I-Claim

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

No B-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

The B-Claim
CLIP I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
Okuda I-Claim
and I-Claim
CTP I-Claim
score I-Claim
. I-Claim

An O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

One- B-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
and I-Premise
9 I-Premise
% I-Premise
vs I-Premise
25 I-Premise
and I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

HRQOL B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

Within O
the O
FLOT65+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
≥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5-fluorouracil O
( O
5-FU O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
FLO O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg/m O
( O
2 O
) O
( O
FLOT O
) O
. O

With O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
LCR O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

The O
stretch O
group O
received O
instruction O
on O
low-load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

Twenty O
men O
with O
established O
bone O
metastases O
secondary O
to O
prostate O
cancer O
were O
randomly O
assigned O
to O
a O
12-week O
resistance O
exercise O
program O
in O
which O
exercise O
prescription O
was O
based O
on O
the O
location O
of O
bone O
lesions O
( O
n=10 O
) O
or O
usual O
care O
( O
n=10 O
) O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2/3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

To O
determine O
whether O
patients O
with O
locally O
advanced O
non-small O
cell O
lung O
cancer O
unsuitable O
for O
resection O
or O
radical O
radiotherapy O
, O
and O
with O
minimal O
thoracic O
symptoms O
, O
should O
be O
given O
palliative O
thoracic O
radiotherapy O
immediately O
or O
as O
needed O
to O
treat O
symptoms O
. O

During B-Claim
RT I-Claim
, I-Claim
nutritional I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar/higher I-Claim
benefit I-Claim
";" I-Claim
in B-Claim
the I-Claim
medium I-Claim
term I-Claim
, I-Claim
only I-Claim
counseling I-Claim
exerted I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

At O
baseline O
and O
three O
follow-up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

QoL O
was O
assessed O
by O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
and O
the O
general O
EuroQol O
five-dimensional O
questionnaire O
( O
EQ-5D O
) O
in O
926 O
chemotherapy-naïve O
patients O
with O
stages O
IIIB O
to O
IV O
NSCLC O
. O

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Spiritual O
well-being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

GJJ O
and O
stent O
placement O
. O

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

In B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
";" O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
-10 O
to O
20-minute O
sessions O
1 O
week O
apart O
. O

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

Chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost/benefit O
ratio O
. O

The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

At B-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
55 I-Premise
% I-Premise
and I-Premise
39 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
( I-Premise
SCL-20 I-Premise
) I-Premise
from I-Premise
baseline I-Premise
compared I-Premise
to I-Premise
34 I-Premise
% I-Premise
and I-Premise
20 I-Premise
% I-Premise
of I-Premise
usual I-Premise
care I-Premise
participants I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.029 I-Premise
) I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
mechanisms I-Premise
for I-Premise
achieving I-Premise
better I-Premise
health I-Premise
, I-Premise
support I-Premise
was I-Premise
found I-Premise
for I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
of I-Premise
distress I-Premise
reduction I-Premise
. I-Premise

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

Forty-one O
patients O
with O
unilateral O
breast-cancer-related O
lymphedema O
for O
at O
least O
3 O
months O
were O
randomly O
grouped O
into O
the O
DLT O
group O
( O
bandage O
group O
, O
N O
= O
21 O
) O
or O
the O
modified O
DLT O
group O
( O
K-tape O
group O
, O
N O
= O
20 O
) O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
family-based O
intervention O
could O
improve O
appraisal O
variables O
( O
appraisal O
of O
illness O
or O
caregiving O
, O
uncertainty O
, O
hopelessness O
) O
, O
coping O
resources O
( O
coping O
strategies O
, O
self-efficacy O
, O
communication O
) O
, O
symptom O
distress O
, O
and O
quality O
of O
life O
in O
men O
with O
prostate O
cancer O
and O
their O
spouses O
. O

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

The O
current O
study O
evaluated O
the O
cost-effectiveness O
of O
the O
capecitabine/docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality-adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

Fifty-one O
of O
84 O
couples O
randomized O
to O
treatment O
completed O
the O
intervention O
( O
61 O
% O
) O
. O

On B-Premise
average I-Premise
, I-Premise
there I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
volumes I-Premise
of I-Premise
tris-acryl I-Premise
microspheres I-Premise
used I-Premise
( I-Premise
9.0 I-Premise
mL I-Premise
vs I-Premise
3.0 I-Premise
mL I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
, I-Premise
whereas O
microcatheter B-Premise
occlusion I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
PVA I-Premise
( I-Premise
28 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild-type I-Premise
KRAS I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
PF I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
-0.7 I-Premise
v I-Premise
-7.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-3.4 I-Premise
v I-Premise
-13.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
BSC I-Premise
. I-Premise

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
TRUE O
acupuncture O
starting O
at O
week O
7 O
. O

The B-Premise
SCNS I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
-14.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-26.2 I-Premise
to I-Premise
-2.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
and I-Premise
-7.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-13.7 I-Premise
to I-Premise
-1.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self-reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.2 I-Premise
to I-Premise
22.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise

The O
original O
analysis O
, O
undertaken O
in O
August O
2003 O
when O
557 O
deaths O
had O
occurred O
, O
showed O
significantly O
better O
survival O
and O
response O
rates O
for O
pain O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
and O
quality O
of O
life O
for O
D3P O
when O
compared O
with O
MP O
. O

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

In O
a O
previously O
conducted O
randomized O
trial O
comparing O
LRP O
with O
ORP O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

Participants B-Premise
randomized I-Premise
to I-Premise
the I-Premise
exercise I-Premise
group I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
by I-Premise
more I-Premise
than I-Premise
100 I-Premise
versus I-Premise
22 I-Premise
% I-Premise
in I-Premise
controls I-Premise
( I-Premise
54.5 I-Premise
vs. I-Premise
14.6 I-Premise
min I-Premise
, I-Premise
P I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
, I-Premise
and I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fitness I-Premise
( I-Premise
increased I-Premise
6-min I-Premise
walk I-Premise
test I-Premise
distance I-Premise
by I-Premise
186.9 I-Premise
vs. I-Premise
81.9 I-Premise
feet I-Premise
, I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
7.1 I-Premise
vs. I-Premise
2.6 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
49 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
39-61 I-Premise
) I-Premise
, I-Premise
OSC I-Premise
51 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
27-57 I-Premise
) I-Premise
- I-Premise
hazard I-Premise
ratio I-Premise
1.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.80-1.53 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
WBRT I-Premise
. I-Premise

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ-5D O
) O
questionnaire O
. O

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
MBAT I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
, I-Claim
sustained I-Claim
benefits I-Claim
across I-Claim
a I-Claim
diverse I-Claim
range I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
particularly I-Claim
those I-Claim
with I-Claim
high I-Claim
stress I-Claim
levels I-Claim
. I-Claim

Although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short- I-Claim
and I-Claim
long-term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

However O
, O
there O
was O
a O
strong O
trend O
towards O
an O
increased O
body O
mass O
among O
patients O
taking O
the O
Juven O
compound O
using O
the O
secondary O
endpoint O
of O
AUC O
. O

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
";" I-Premise
p=0.026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
";" I-Premise
p=0.0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.24 I-Premise
) I-Premise
. I-Premise

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine-carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

Pain O
was O
assessed O
with O
the O
BPI-SF O
questionnaire O
, O
and O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Prostate O
( O
FACT-P O
) O
questionnaire O
. O

The O
QoL O
was O
evaluated O
by O
the O
Spitzer O
QL-Index O
and O
by O
the O
EORTC O
QLQ-C30+LC O
13 O
questionnaires O
before O
chemotherapy O
, O
after O
one O
cycle O
, O
after O
three O
cycles O
, O
and O
then O
every O
6 O
weeks O
in O
the O
first O
6 O
months O
and O
every O
3 O
months O
thenafter O
. O

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
34 I-Premise
and I-Premise
33.7 I-Premise
months I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.94 I-Premise
) I-Premise
. I-Premise

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

The B-Premise
median I-Premise
TDD I-Premise
in I-Premise
HRQOL I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
versus I-Premise
5.8 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0084 I-Premise
) I-Premise
. I-Premise

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Patients O
with O
platinum-sensitive O
recurrent O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
plus O
carboplatin O
or O
carboplatin O
alone O
, O
every O
21 O
days O
. O

The O
primary O
outcome O
for O
these O
quality-of-life O
analyses O
was O
time O
to O
worsening O
of O
symptoms O
, O
analysed O
for O
all O
randomised O
patients O
. O

A B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone-resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg/d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1,600 I-Premise
mg/d I-Premise
. I-Premise

Letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
QOL I-Claim
. I-Claim

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg/m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well-being I-Claim
. I-Claim

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Seventy-one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11.0 I-Premise
g/dL I-Premise
. I-Premise

At B-Premise
2 I-Premise
weeks I-Premise
, I-Premise
assignment I-Premise
to I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
( I-Premise
-0.25 I-Premise
points I-Premise
on I-Premise
a I-Premise
5-point I-Premise
scale I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-0.43 I-Premise
to I-Premise
-0.06 I-Premise
, I-Premise
P=.01 I-Premise
) I-Premise
but B-Premise
not I-Premise
in I-Premise
pain I-Premise
severity I-Premise
( I-Premise
-0.21 I-Premise
points I-Premise
on I-Premise
an I-Premise
11-point I-Premise
scale I-Premise
, I-Premise
-0.60 I-Premise
to I-Premise
0.17 I-Premise
, I-Premise
P=.27 I-Premise
) I-Premise
. I-Premise

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow-up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

Thirty-two B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
19 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
experienced I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
adverse I-Premise
events I-Premise
( I-Premise
graded I-Premise
using I-Premise
the I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
Common I-Premise
Toxicity I-Premise
Criteria I-Premise
[ I-Premise
version I-Premise
2.0 I-Premise
] I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Mean B-Premise
sexual I-Premise
function I-Premise
score I-Premise
was I-Premise
15 I-Premise
points I-Premise
lower I-Premise
at I-Premise
3 I-Premise
years I-Premise
for I-Premise
the I-Premise
cryoablation I-Premise
group I-Premise
and I-Premise
13 I-Premise
% I-Premise
more I-Premise
of I-Premise
the I-Premise
cryoablation I-Premise
men I-Premise
said I-Premise
that I-Premise
sexuality I-Premise
was I-Premise
a I-Premise
moderate I-Premise
or I-Premise
big I-Premise
problem I-Premise
. I-Premise

We O
aimed O
to O
determine O
the O
effect O
of O
dietary O
counseling O
or O
oral O
supplements O
on O
outcome O
for O
patients O
with O
cancer O
, O
specifically O
, O
nutritional O
outcome O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
, O
during O
and O
3 O
months O
after O
radiotherapy O
. O

We O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O

Patient O
QOL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
and O
the O
UNISCALE O
QOL O
questionnaires O
. O

1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O

To O
assess O
the O
long O
term O
risks O
and O
benefits O
of O
hormone O
replacement O
therapy O
( O
combined O
hormone O
therapy O
versus O
placebo O
, O
and O
oestrogen O
alone O
versus O
combined O
hormone O
therapy O
) O
. O

Effects O
varied O
by O
intervention O
dose O
. O

Of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
extensive-stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

The O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
CRT O
. O

The O
2 O
+ O
2.5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

The B-Claim
role I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
in I-Claim
postmenopausal I-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
controversial I-Claim
. I-Claim

Adjuvant B-Claim
immunotherapy I-Claim
with I-Claim
whole-cell I-Claim
lysate I-Claim
dendritic I-Claim
cell I-Claim
vaccine I-Claim
may I-Claim
improve I-Claim
short-term I-Claim
survival I-Claim
. I-Claim

Potential O
prognostic O
factors O
were O
studied O
in O
187 O
women O
with O
baseline O
QL O
data O
from O
a O
trial O
of O
paclitaxel O
versus O
doxorubicin O
as O
first-line O
chemotherapy O
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

